EP2768524
ÓNÆMISMEÐFERÐ BYGGÐ Á PD-L1
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
17.10.2012EP published:
4.5.2022EP application number:
12780408.6
EP translation filed:
23.6.2022Grant published:
15.8.2022EPO information:
European Patent Register
Max expiry date:
16.10.2032Expiry date:
16.10.2026Next due date:
31.10.2026
Title in English:
PD-L1 BASED IMMUNOTHERAPYLanguage of the patent:
English
Timeline
Today
17.10.2012EP application
4.5.2022EP Publication
23.6.2022Translation submitted
15.8.2022Registration published
16.10.2026Expires
Owner
Name:
IO Biotech ApSAddress:
Ole Maaløes Vej 3, 2200 Copenhagen N, DK
Inventor
Name:
ANDERSEN, Mads HaldAddress:
2850 Nærum, DK
Agent
Name:
Tego IP ehf.Address:
Pósthólf 8129, 128, Reykjavík,
Priority
Number:
201170574 PDate:
17.10.2011Country:
DK
Classification
Categories:
A61K 39/00, A61P 35/00, C07K 14/705
Annual fees
Number
Paid
Expires
Payer
Number: 11
Paid: 7.9.2022
Expires: 16.10.2023
Payer: Árnason Faktor ehf.
Number: 12
Paid: 13.10.2023
Expires: 16.10.2024
Payer: Árnason Faktor ehf.
Number: 13
Paid: 17.9.2024
Expires: 16.10.2025
Payer: Árnason Faktor ehf.
Number: 14
Paid: 8.10.2025
Expires: 16.10.2026
Payer: Árnason Faktor ehf.